Glaukos Highlights Innovation in May 2025 Presentation

The latest update is out from Glaukos ( (GKOS) ).

Glaukos Corporation announced its May 2025 Investor Presentation, highlighting its commitment to innovation in treating chronic eye diseases. The company has invested over $700 million in R&D since 2018 and expanded its pipeline from 4 to 14 programs by 2025. The presentation emphasized the iDose TR, a groundbreaking sustained-release drug delivery system designed to improve patient compliance in glaucoma treatment. Glaukos aims to disrupt traditional treatment paradigms with its novel therapies, focusing on establishing robust growth engines and expanding market access.

The most recent analyst rating on (GKOS) stock is a Buy with a $131.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.

Spark’s Take on GKOS Stock

According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.

Glaukos’ overall score reflects strong revenue growth and a solid financial position. However, persistent operational and cash flow challenges, bearish technical indicators, and high valuation relative to earnings weigh significantly on the score. Positive elements from the earnings call offer some optimism, but significant risks remain.

To see Spark’s full report on GKOS stock, click here.

More about Glaukos

Glaukos Corporation operates in the medical technology industry, focusing on innovative solutions for chronic eye diseases. The company is known for its micro-scale surgical devices and sustained-release pharmaceuticals, with a market focus on glaucoma, keratoconus, ocular cancer, and other anterior and posterior segment eye conditions.

Average Trading Volume: 1,149,894

Technical Sentiment Signal: Hold

Current Market Cap: $5.41B

See more data about GKOS stock on TipRanks’ Stock Analysis page.